Literature DB >> 15088256

Autonomic failure in neurodegenerative disorders.

Horacio Kaufmann1, Italo Biaggioni.   

Abstract

Autonomic failure with orthostatic and postprandial hypotension, bowel and bladder disturbances, and sexual dysfunction are frequent, disabling features in patients with the three most prevalent neurodegenerative movement disorders: Parkinson's disease (PD), dementia with Lewy bodies and multiple system atrophy (MSA), and the related neurodegenerative Lewy-body disorder characterized by isolated severe autonomic failure (pure autonomic failure, PAF). All of these disorders have in common the presence of alpha-synuclein in the cytoplasmic precipitates found in neurons in Lewy body disorders or glia in MSA. Autonomic failure with disabling orthostatic hypotension is the clinical hallmark of PAF. It may also be the initial presentation of MSA, making diagnosis difficult. Within a few years, however, MSA patients develop movement disorders, which are differentiated from PD by the paucity of unilateral resting tremor, the lack of response to levodopa, and their rapidly progressive nature, resulting in disability and death in 7 to 8 years. Moderately effective treatment is available for autonomic symptoms, but management of movement disorders remains unsuccessful. Discoveries relevant to physiology and common pathological conditions were initially made in patients with autonomic failure. Meals induce profound hypotension in these patients. Conversely, commonly used nasal decongestants can produce substantial pressor effects. Even 500 mL of water can increase blood pressure by a previously unrecognized sympathetic reflex. Residual sympathetic tone is able to induce sustained supine hypertension in MSA, because it is resolved after ganglionic blockade. These phenomena were not previously recognized because of the buffering capacity of the baroreflex, but were unmasked in autonomic failure patients.

Entities:  

Mesh:

Year:  2003        PMID: 15088256     DOI: 10.1055/s-2004-817719

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  45 in total

1.  Afferent baroreflex failure in familial dysautonomia.

Authors:  Lucy Norcliffe-Kaufmann; Felicia Axelrod; Horacio Kaufmann
Journal:  Neurology       Date:  2010-11-23       Impact factor: 9.910

Review 2.  Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases.

Authors:  David S Goldstein
Journal:  Cell Mol Neurobiol       Date:  2012-07       Impact factor: 5.046

3.  Treatment of dysautonomia in extrapyramidal disorders.

Authors:  Tjalf Ziemssen; Heinz Reichmann
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

4.  Autonomics and cognition.

Authors:  Martin A Goldstein; Michael E Silverman
Journal:  Clin Auton Res       Date:  2006-04       Impact factor: 4.435

5.  Epidemiology, Diagnosis, and Management of Neurogenic Orthostatic Hypotension.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Mov Disord Clin Pract       Date:  2017-03-16

Review 6.  Other autonomic neuropathies associated with ganglionic antibody.

Authors:  Paola Sandroni; Phillip A Low
Journal:  Auton Neurosci       Date:  2008-12-04       Impact factor: 3.145

Review 7.  Management of neurogenic orthostatic hypotension in patients with autonomic failure.

Authors:  Christoph Schroeder; Jens Jordan; Horacio Kaufmann
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

8.  Cardiac ectopy in chronic autonomic failure.

Authors:  David S Goldstein
Journal:  Clin Auton Res       Date:  2009-12-11       Impact factor: 4.435

9.  Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension.

Authors:  Yehonatan Sharabi; Richard Imrich; Courtney Holmes; Sandra Pechnik; David S Goldstein
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

10.  Association of anosmia with autonomic failure in Parkinson disease.

Authors:  David S Goldstein; LaToya Sewell; Courtney Holmes
Journal:  Neurology       Date:  2010-01-19       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.